{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+70+mg+%2F+140+mg", "query": { "intervention": "Placebo for 70 mg / 140 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+70+mg+%2F+140+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T00:31:46.208Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02737306", "title": "A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Vs Host Disease" ], "interventions": [ { "name": "PRO 140", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2017-05-14", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 8, "location_summary": "Miami, Florida • Maywood, Illinois • Detroit, Michigan + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02737306" }, { "nct_id": "NCT01534273", "title": "A Study of LY2886721 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "LY2886721", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 30, "start_date": "2012-02", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534273" }, { "nct_id": "NCT01147666", "title": "Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End Stage Renal Disease", "Anemia" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 161, "start_date": "2010-05-17", "completion_date": "2012-10-15", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 25, "location_summary": "Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Azusa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147666" }, { "nct_id": "NCT01375777", "title": "Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "BIOLOGICAL" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo to Evolocumab", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 411, "start_date": "2011-07-06", "completion_date": "2012-03-02", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375777" }, { "nct_id": "NCT01380730", "title": "LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "BIOLOGICAL" }, { "name": "Placebo to Evolocumab", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 631, "start_date": "2011-07-01", "completion_date": "2012-04-05", "has_results": true, "last_update_posted_date": "2022-11-15", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Malvern", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01380730" }, { "nct_id": "NCT00558844", "title": "Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Arikayce™ 560 mg", "type": "DRUG" }, { "name": "Placebo for 560 mg", "type": "DRUG" }, { "name": "Arikayce™ 70 mg", "type": "DRUG" }, { "name": "Arikayce™ 140 mg", "type": "DRUG" }, { "name": "Placebo for 70 mg / 140 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 41, "start_date": "2008-01", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2019-06-04", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00558844" }, { "nct_id": "NCT01341470", "title": "A Study of LY2495655 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "LY2495655", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "24 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "24 Years to 85 Years" }, "enrollment_count": 47, "start_date": "2011-05", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2019-06-17", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01341470" }, { "nct_id": "NCT04366349", "title": "A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Asthma" ], "interventions": [ { "name": "melrilimab (GSK3772847) 70 milligram (mg)", "type": "BIOLOGICAL" }, { "name": "melrilimab (GSK3772847) 140 milligram (mg)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 65, "start_date": "2020-07-21", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04366349" }, { "nct_id": "NCT01952574", "title": "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Erenumab PFS", "type": "DRUG" }, { "name": "Erenumab AI/Pen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 483, "start_date": "2013-08-06", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Long Beach, California • National City, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01952574" }, { "nct_id": "NCT04634409", "title": "A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Bamlanivimab", "type": "DRUG" }, { "name": "Etesevimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "VIR-7831", "type": "DRUG" }, { "name": "Bebtelovimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1755, "start_date": "2020-10-29", "completion_date": "2021-10-18", "has_results": true, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-10-07T00:31:46.208Z", "location_count": 127, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634409" } ] }